Haematologica, Vol 93, Issue 2, 169-172 doi:10.3324/haematol.12002
Copyright © 2008 by Ferrata Storti Foundation
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teofili, L.
Right arrow Articles by Larocca, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teofili, L.
Right arrow Articles by Larocca, L. M.

Editorials and Perspectives

Childhood polycythemia vera and essential thrombocythemia: does their pathogenesis overlap with that of adult patients?

Luciana Teofili1, Robin Foà2, Fiorina Giona2, Luigi Maria Larocca3

1 Department of Hematology, Catholic University;
2 Division of Hematology, Department of Cellular Biotechnologies and Hematology, "La Sapienza" University;
3 Department of Pathology, Catholic University, Rome, Italy. E-mail: llarocca{at}rm.unicatt.it

The incidence of polycythemia vera (PV) and essential thrombocythemia (ET) in children and adolescents is extremely low. The annual incidence of PV in patients aged less than 20 years is estimated to be about 2 new cases every 10 million people.1 Similarly, the annual incidence of ET ranges from 1 to 4 new cases every 10 million people.1–3 Therefore, on the whole it can be assumed that PV and ET are between 40 and 90 fold less frequent in children than in adults. The rarity of pediatric PV and ET has determined that, for many years, data on their clinical presentation and biologic features have been sparse and anecdotal.4–10 Furthermore, it has been generally accepted that specific diagnostic criteria developed for adult patients with PV and ET should also apply to pediatric cases.11,12 Two recent reviews have extensively evaluated the pathogenesis of primary erythrocytosis and thrombocytosis (myeloproliferations independent of external influences) occurring in childhood.13,14 The authors indicate that, as in the adult population, pediatric age PV and ET can also present as sporadic diseases.12,13 In addition, they underline that several cases of PV and ET reported in children are in fact familial diseases, caused by hereditary defects consisting of specific mutations of the erythropoietin receptor, thrombopoietin or MPL genes.15–20

To date, the discovery of specific genetic defects in adult Ph-negative myeloproliferative diseases (MPDs) has provided fresh insights into the understanding of the molecular pathogenesis of these disorders. Indeed, almost all patients with PV and about half of the patients with ET harbor a somatic point mutation in a highly conserved residue of the pseudokinase domain of the JAK2 tyrosine kinase, the JAK2V617F mutation.21–25 Furthermore, in the rare PV patients who proved JAK2V617F negative, other functionally similar JAK2 mutations involving the exon 12 have been described.26 In addition to the presence of specific molecular alterations, the vast majority of female patients with PV, and a significant proportion of those with ET, show a clonal expansion of hematopoiesis, indicating the neoplastic nature of the myeloproliferation.27 These specific MPD markers have been recently investigated in familial clusters of MPDs to explore whether JAK2 mutations could also be present in the germ line, as reported for mutations of the erythropoietin receptor, thrombopoietin or MPL genes.28–32 The results obtained have clarified that JAK2V617F is a somatic mutation secondarily acquired in this set of patients, occurring as frequently as in sporadic cases. In addition, like sporadic MPDs, these patients may also exhibit a clonal expansion of hematopoiesis.28–32 Although the primary pathogenetic alteration underlying this type of familial MPD still has to be defined, unlike the mutations of the erythropoietin receptor, thrombopoietin and MPL genes15–20 it does not appear to be hereditary.28–32 Interestingly, members belonging to the same family can develop MPDs with different phenotypes.28–32 This topic has been recently discussed in a well-presented review by Skoda and Prchal.33

The increasing knowledge accumulated over recent years in adult MPDs has prompted hematologists to reconsider pediatric PV and ET.34–36 We have recently published a study carried out in 38 consecutive children with PV and ET,34 diagnosed in accordance with the criteria in use at the time of their first evaluation.11, 12 Among them, a patient with PV and 11 children with ET had a familial history of MPD. We have investigated the entire cohort of patients, including cases with a familial occurrence, for the presence of endogenous erythroid colony (EEC) growth, granulocyte PRV-1 RNA over-expression, JAK2V617F mutation and clonal hematopoiesis. Furthemore, in familial cases, mutations of the erythropoietin receptor, thrombopoietin and MPL genes were investigated. We found that 9 out of 11 patients with familial thrombocytosis showed an inherited activating mutation of MPL.20 Indeed, the first important observation of this study was the high frequency of hereditary forms in this unselected series of patients. Although the exact prevalence of hereditary disorders in our patient population could be overestimated, since 12 patients belonged to 5 different families, their overall occurrence in pediatric patients is undoubtedly noteworthy. We observed that children with familial disorders did not exhibit the JAK-2V617F mutation, always had a polyclonal hematopoiesis, and rarely showed EEC growth and PRV-1 RNA over-expression.34 These data indicate that in children investigated for PV or ET, a careful screening for familial thrombocytosis and erythrocytosis is mandatory, since familial MPDs observed at this age are most likely due to inherited, although often unknown, defects. Importantly, the identification of specific hereditary defects could help these young patients to avoid more invasive diagnostic approaches, such as a bone marrow biopsy. Among 26 children with non-familial MPD, the prevalence of the JAK2V617F mutation was similar in PV (37%) and ET (38%), while a significant proportion of female patients had a clonal hematopoiesis.34 The incidence of JAK-2V617F mutation in children with PV was significantly lower than in adult patients with PV investigated as control group (92% vs. 37%).34 By contrast, the difference in the proportion of JAK2V617F mutated patients between adults and children with ET appeared less pronounced (58% vs. 38%).34 In a previous study published in Blood by Randi et al.,35 of 20 children with sporadic ET diagnosed according to the PVSG criteria 11 were examined for the presence of the JAK2V617F mutation and for the clonality of hematopoiesis. The authors found that only 4 of them (25%) exhibited the JAK2V617F mutation and that the hematopoiesis was clonal in 4 out of the 15 female patients (28.5%). These findings differed significantly from the detection of 60% of JAK2V617F mutated patients and of 45% of clonal patients among the 47 adults with ET.35 More recently, El-Monheim et al. evaluated the presence of the JAK2V617F mutation in 9 children with primary thrombocytosis.36 While the bone marrow histology was suggestive of ET in all patients, the JAK2V617F mutation was detected only in 1 patient.36 On the whole, the data that have emerged from these studies indicate that children with PV and ET harbor the JAK2V617F mutation much less frequently than adults.34–36 Although it could be speculated that children showing a wild type JAK2 may become JAK2V617F positive at a later stage, the presence of EEC growth and of PRV-1 RNA over-expression in patients who proved negative for the JAK2V617F mutation34 suggests that, in pediatric MPDs, other molecular defects, functionally similar to the JAK2V617F mutation, could affect the JAK2 dependent signaling pathway.

At the time of writing, we have been investigating 47 consecutive children, of whom 19 had a familial MPD (5 PV and 14 with ET). We identified the MPL activating mutation in 3 further patients with familial thrombocytosis, while no hereditary genetic defects were found in the new cases of familial PV. In addition, all children with PV were investigated for the exon 12 JAK2 mutations,26 but no case carrying these mutations was found.

On the whole, the findings obtained by our group confirm that pediatric erythrocytosis and thrombocytosis are heterogeneous diseases, including both sporadic and hereditary disorders. In adult patients, the presence of JAK2 mutations plays a pivotal role in the classification of MPDs37 and offers the opportunity to modify the current diagnostic approach, based on the exclusion of a secondary myeloproliferation38. In contrast, pediatric cases often recognize different pathogenetic mechanisms. We have recently demonstrated that the proposed diagnostic guidelines of MPDs based on the detection of JAK2 mutations38 are not appropriate for pediatric patients39. Indeed, in the case of childhood MPDs, it should first be established if the disease is congenital or acquired. For this purpose, the first step of the diagnostic screening should investigate the possible presence of a familial occurrence suggestive of the congenital origin of MPD. In fact, this set of patients has a very low probability of carrying JAK2 mutations while they could exhibit hereditary mutations of the erythropoietin receptor, thrombopoietin or MPL genes. In addition, as recently suggested,34–36 JAK2 mutations are detectable only in a minority of children with non-familial PV and ET. For the diagnosis of all other cases, the extensive investigation of complementary MPD markers, such as clonality of hematopoiesis, EEC growth or PRV-1 RNA over-expression should be performed. In line with these observations, we propose a specific diagnostic approach for childhood MPDs (see Figure 1). Meanwhile, it is hoped that studies investigating alternative pathogenetic mechanisms in adult patients with wild type JAK2 MPDs will help to clarify the genetic alterations underlying childhood PV and ET.


Figure 193169
View larger version (16K):
[in this window]
[in a new window]
[Download PPT slide]
  		Figure 1. Proposed diagnostic algorithm for childhood polycythemia (A) and thrombocythemia (B).

References

  1. McNally RJ, Rowland D, Roman E, Cartwright RA. Age and sex distributions of hematological malignancies in the U.K. Hematol Oncol 1997;15:173-89.[CrossRef][Web of Science][Medline]
  2. Jensen MK, de Nully Brown P, Nielsen OJ, Hasselbalch HC. Incidence, clinical features and outcome of essential thrombocythaemia in a well defined geographical area. Eur J Haematol 2000;65:132-9.[CrossRef][Web of Science][Medline]
  3. Hasle H. Incidence of essential thrombocythaemia in children. Br J Haematol 2000;110:751.[Web of Science][Medline]
  4. Marlow AA, Fairbanks VF. Polycythemia vera in an eleven-year-old girl. N Engl J Med 1960;263:950-2.[Web of Science][Medline]
  5. Danish EH, Rasch CA, Harris JW. Polycythemia vera in childhood: case report and review of the literature. Am J Hematol 1980;9:421-8.[Web of Science][Medline]
  6. Chistolini A, Mazzucconi MG, Ferrari A, la Verde G, Ferrazza G, Dragoni F, et al. Essential thrombocythemia: a retrospective study on the clinical course of 100 patients. Haematologica 1990;75:537-40.[Web of Science][Medline]
  7. Perea G, Remacha A, Besses C, Jimenez M, Florensa L, Cervantes F. Is polycythemia vera a serious disease in young adults? Haematologica 2001;86:543-4.[Free Full Text]
  8. Turker M, Ozer EA, Oniz H, Atabay B, Yaprak I. Polycythemia vera in a 12-year-old girl: a case report. Pediatr Hematol Oncol 2002;19:263-6.[CrossRef][Web of Science][Medline]
  9. Randi ML, Putti MC, Fabris F, Sainati L, Zanesco L, Girolami A. Features of essential thrombocythaemia in childhood: a study of five children. Br J Haematol 2000;108:86-9.[CrossRef][Web of Science][Medline]
  10. Florensa L, Zamora L, Besses C, Ortega JJ, Bastida P, Toll T, et al. Cultures of myeloid progenitor cells in pediatric essential thrombocythemia. Leukemia 2002;16:1876-7.[CrossRef][Web of Science][Medline]
  11. Michiels JJ, Juvonen E. Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group. Semin Thromb Hemost 1997;23:339-47.[Medline]
  12. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood 2002;100:2292-302.[Abstract/Free Full Text]
  13. Cario H. Childhood polycythemias/erythrocytoses: classification, diagnosis, clinical presentation, and treatment. Ann Hematol 2005;84:137-45.[CrossRef][Web of Science][Medline]
  14. Dame C, Sutor AH. Primary and secondary thrombocytosis in childhood. Br J Haematol 2005;129:165-77.[CrossRef][Web of Science][Medline]
  15. Kralovics R, Indrak K, Stopka T, Berman BW, Prchal JF, Prchal JT. Two new EPO receptor mutations: truncated EPO receptors are most frequently associated with primary familial and congenital polycythemias. Blood 1997;90:2057-61.[Abstract/Free Full Text]
  16. Wiestner A, Schlemper RJ, van der Maas AP, Skoda RC. An activating splice donor mutation in the thrombopoietin gene causes hereditary thrombocythaemia. Nat Genet 1998;18:49-52.[CrossRef][Web of Science][Medline]
  17. Ghilardi N, Wiestner A, Kikuchi M, Ohsaka A, Skoda RC. Hereditary thrombocythaemia in a Japanese family is caused by a novel point mutation in the thrombopoietin gene. Br J Haematol 1999;107:310-16.[CrossRef][Web of Science][Medline]
  18. Kondo T, Okabe M, Sanada M, Kurosawa M, Suzuki S, Kobayashi, et al. Familial essential thrombocythemia associated with one-base deletion in the 5'-untranslated region of the thrombopoietin gene. Blood 1998;92:1091-96.[Abstract/Free Full Text]
  19. Ghilardi N, Skoda RC. A single-base deletion in the thrombopoietin (TPO) gene causes familial essential thrombocythemia through a mechanism of more efficient translation of TPO mRNA. Blood 1999;94:1480-2.[Free Full Text]
  20. Ding J, Komatsu H, Wakita A, Kato-Uranishi M, Ito M, Satoh A, et al. Familial essential thrombocythemia associated with a dominant-positive activating mutation of the MPL gene, which encodes for the receptor for thrombopoietin. Blood 2004;103:4198-200.[Abstract/Free Full Text]
  21. Zhao R, Xing S, Li Z, Fu X, Li Q, Krantz SB, et al. Identification of an acquired JAK2 mutation in polycythemia vera. J Biol Chem 2005;280:22788-92.[Abstract/Free Full Text]
  22. Baxter EJ, Scott LM, Campbell PJ, East C, Fourouclas N, Swanton S, et al. Acquired mutation of the tyrosine kinase JAK2 in human myeloproliferative disorders. Lancet 2005;365:1054-61.[Web of Science][Medline]
  23. James C, Ugo V, Le Couedic JP, Staerk J, Delhommeau F, Lacout C, et al. A unique clonal JAK2 mutation leading to constitutive signalling causes polycythaemia vera. Nature 2005;434:1144-8.[CrossRef][Medline]
  24. Kralovics R, Passamonti F, Buser AS, Teo SS, Tiedt R, Passweg JR, et al. A gain-of-function mutation of JAK2 in myeloproliferative disorders. N Engl J Med 2005;352:1779-90.[Abstract/Free Full Text]
  25. Levine RL, Wadleigh M, Cools J, Ebert BL, Wernig G, Huntly BJ, et al. Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell 2005;7:387-97.[CrossRef][Web of Science][Medline]
  26. Scott LM, Tong W, Levine RL, Scott MA, Beer PA, Stratton MR, et al. JAK2 exon 12 mutations in polycythemia vera and idiopathic erythrocytosis. N Engl J Med 2007;356:459-68.[Abstract/Free Full Text]
  27. Spivak JL. The chronic myeloproliferative disorders: clonality and clinical heterogeneity. Semin Hematol 2004;41 Suppl_3: 1-5.[Web of Science][Medline]
  28. Bellanne-Chantelot C, Chaumarel I, Labopin M, Bellanger F, Barbu V, De Toma C, et al. Genetic and clinical implications of the Val617Phe JAK2 mutation in 72 families with myeloproliferative disorders. Blood 2006;108:346-52.[Abstract/Free Full Text]
  29. Rumi E, Passamonti F, Pietra D, Della Porta MG, Arcaini L, Boggi S, et al. JAK2 (V617F) as an acquired somatic mutation and a secondary genetic event associated with disease progression in familial myeloproliferative disorders. Cancer 2006;107:2206-11.[CrossRef][Medline]
  30. Cario H, Goerttler PS, Steimle C, Levine RL, Pahl HL. The JAK2V617F mutation is acquired secondary to the predisposing alteration in familial polycythaemia vera. Br J Haematol 2005;130:800-1.[CrossRef][Web of Science][Medline]
  31. Pardanani A, Lasho T, McClure R, Lacy M, Tefferi A. Discordant distribution of JAK2V617F mutation in siblings with familial myeloproliferative disorders. Blood 2006;107:4572-3.[Free Full Text]
  32. Kralovics R, Stockton DW, Prchal JT. Clonal hematopoiesis in familial polycythemia vera suggests the involvement of multiple mutational events in the early pathogenesis of the disease. Blood 2003;102:3793-6.[Abstract/Free Full Text]
  33. Skoda R, Prchal JT. Lessons from familial myeloproliferative disorders. Semin Hematol 2005;42:266-73.[CrossRef][Web of Science][Medline]
  34. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. Markers of myeloproliferative diseases in childhood polycythemia vera and essential thrombocythemia. J Clin Oncol 2007;25:1048-52.[Abstract/Free Full Text]
  35. Randi ML, Putti MC, Scapin M, Pacquola E, Tucci F, Micalizzi C, et al. Pediatric patients with essential thrombocythemia are mostly polyclonal and V617FJAK2 negative. Blood 2006;108:3600-2.[Abstract/Free Full Text]
  36. El-Moneim AA, Kratz CP, Boll S, Rister M, Pahl HL, Niemeyer CM. Essential versus reactive thrombocythemia in children: retrospective analyses of 12 cases. Pediatr Blood Cancer 2007;49:52-5.[CrossRef][Web of Science][Medline]
  37. Campbell PJ, Green AR. The myeloproliferative disorders. N Engl J Med 2006;355:2452-66.[Free Full Text]
  38. Tefferi A, Thiele J, Orazi A, Kvasnicka HM, Barbui T, Hanson CA, et al. Proposals and rationale for revision of the World Health Organization diagnostic criteria for polycythemia vera, essential thrombocythemia, and primary myelofibrosis: recommendations from an ad hoc international expert panel. Blood 2007;110:1092-7.[Abstract/Free Full Text]
  39. Teofili L, Giona F, Martini M, Cenci T, Guidi F, Torti L, et al. The revised WHO diagnostic criteria for Ph-negative myeloproliferative diseases are not appropriate for the diagnostic screening of childhood polycythemia vera and essential thrombocythemia. Blood 2007;110:3384-6.[Abstract/Free Full Text]



This article has been cited by other articles:


Home page
 haematolHome page
L. Teofili, F. Giona, L. Torti, T. Cenci, B. M. Ricerca, C. Rumi, V. Nunes, R. Foa, G. Leone, M. Martini, et al.
Hereditary thrombocytosis caused by MPLSer505Asn is associated with a high thrombotic risk, splenomegaly and progression to bone marrow fibrosis
Haematologica, January 1, 2010; 95(1): 65 - 70.
[Abstract] [Full Text] [PDF]

Home page
 haematolHome page
M. Martini, L. Teofili, T. Cenci, F. Giona, L. Torti, M. Rea, R. Foa, G. Leone, and L. M. Larocca
A novel heterozygous HIF2AM535I mutation reinforces the role of oxygen sensing pathway disturbances in the pathogenesis of familial erythrocytosis
Haematologica, July 1, 2008; 93(7): 1068 - 1071.
[Abstract] [Full Text] [PDF]

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Teofili, L.
Right arrow Articles by Larocca, L. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Teofili, L.
Right arrow Articles by Larocca, L. M.